Thermo Fisher Scientific Inc. Issues $2.5 Billion in Senior Notes

Details

issued $2.5 billion aggregate principal amount of Senior Notes due between 2031 and 2037. The proceeds from the sale will be used for general corporate purposes, including potential acquisitions, debt repayment, and capital expenditures. The notes are unsecured obligations, ranking senior to subordinated debt and structurally subordinated to secured debt and other liabilities.

Items reported

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is a world-leading biotechnology company that provides essential tools and services for life sciences, biotechnology, pharmaceutical, and healthcare industries. Renowned for its extensive portfolio, the company specializes in offering innovative laboratory products, analytical instruments, and software solutions critical for research, diagnostics, and clinical applications. Thermo Fisher enables scientists to perform complex experiments with cutting-edge technology, from DNA sequencing and cell analysis to clinical diagnostics and specialty chemicals. Serving a vast array of sectors, the company impacts fields such as diagnostics, genetic engineering, and environmental monitoring. Its strategic acquisitions and collaborations strengthen its market presence, making it a go-to partner for scientific advancements and innovation. With operations spanning over 50 countries, Thermo Fisher plays a pivotal role in driving scientific discovery and improving health outcomes globally.